Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  MEDNAX Inc    MD

MEDNAX INC (MD)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Law Offices of Howard G. Smith Announces Investigation on Behalf of Mednax, Inc. Investors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/14/2018 | 03:36am CEST

Law Offices of Howard G. Smith announces an investigation on behalf of Mednax, Inc. (“Mednax” or the “Company) (NYSE: MD) investors concerning the Company and its officers’ possible violations of federal securities laws.

On April 20, 2017, Mednax announced poor financial results for the first quarter of 2017, including missed earnings. Mednax also reported that “[s]ame-unit revenue from net reimbursement-related factors is expected to decline by 0.6 percent for the first quarter of 2017, compared to the first quarter of 2016, driven by a 90 basis point payor mix shift to government payors that impacted same-unit pricing negatively by 150 basis points.” On this news, Mednax’s share price fell $5.39, or 8.1%, to close at $61.30 per share on April 20, 2017.

Then, on July 28, 2017, during its second quarter earnings call, Mednax announced that the Company had failed to complete acquisitions of anesthesiologist practices during the quarter and that any future anesthesiologist acquisitions were unlikely, citing the “challenging” payor mix combined with “continued … growth in compensation expense for nurse anesthetists.” On this news, Mednax’s share price fell $8.76 or 15.5%, to close at $47.73 per share on July 28, 2017, thereby further injuring investors.

If you purchased Mednax securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDNAX INC
09/14MEDNAX : Launches Audiology Institute
AQ
09/14MD LOSS NOTICE : Rosen Law Firm Announces Filing of Securities Class Action Laws..
PR
09/12MEDNAX LAUNCHES AUDIOLOGY INSTITUTE : Nation’s Largest Provider of Newborn..
BU
09/11MEDNAX INC : Lawsuit for Investors in Shares of MEDNAX, Inc. (NYSE: MD) Announce..
AC
09/08MEDNAX INC : Kaskela Law LLC Announces Class Action Lawsuit Against Mednax, Inc...
AC
09/08MEDNAX INC : FINAL DEADLINE MONDAY: The Schall Law Firm Announces the Filing of ..
AC
09/08MEDNAX INC : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Me..
AC
09/06MEDNAX INC : STOCKHOLDER ALERT: Kaskela Law LLC Announces Class Action Lawsuit A..
AC
09/05MEDNAX INC : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Me..
AC
09/05SEPTEMBER 10TH DEADLINE ALERT : Glancy Prongay & Murray LLP Reminds Investors of..
BU
More news
News from SeekingAlpha
09/14Huge Opportunity With This Profitable Medical Company 
09/07I Find Better Stocks For You - Introducing Good Stocks@Bargain Prices 
09/04MEDNAX commences $250M accelerated share repurchase program 
08/23MEDNAX appoints Stephen D. Farber as Executive Vice President 
08/22Outpatient care providers in the green 
Financials ($)
Sales 2018 3 668 M
EBIT 2018 478 M
Net income 2018 285 M
Debt 2018 1 684 M
Yield 2018 -
P/E ratio 2018 14,84
P/E ratio 2019 13,12
EV / Sales 2018 1,62x
EV / Sales 2019 1,66x
Capitalization 4 262 M
Chart MEDNAX INC
Duration : Period :
MEDNAX Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDNAX INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 51,2 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Roger J. Medel Chief Executive Officer & Director
Joseph M. Calabro President & Chief Operating Officer
Cesar L. Alvarez Chairman
Vivian Lopez-Blanco Chief Financial Officer & Treasurer
Robert C. Bryant Chief Information Officer & Senior Vice President
Sector and Competitors